产品中心/ PRODUCTS

我的位置:首页  >  产品中心  >  基质胶  >  标准型基质胶  >  基质胶
基质胶
  • 产品型号:
  • 厂商性质:生产厂家
  • 更新时间:2025-07-17
  • 访  问  量:9
简要描述:

适用于与细胞增殖或分化相关的2D或3D培养,也适用于细胞形态学研究。常被应用于肿瘤细胞的迁移或侵袭、体外血管生成、主动脉环和细胞球培养等。蛋白浓度:8-12 mg/mL

在线咨询

联系电话:400-091-6556

产品详情


Mogengel Matrix

标准型基质胶

1、 产品描述

模基生物标准型基质胶是从富含胞外基质蛋白的小鼠肿瘤中提取出的天然基底膜基质。主要依次为层粘连蛋白(Laminin)、IV型胶原蛋白(Col-IV)、巢蛋白(Entactin)、硫酸乙酰肝素蛋白多糖(Heparan sulphate proteoglycans)及多种细胞因子,如类胰岛素生长因子(IGF-1)、转化生长因子β(TGF-β)、血管内皮生长因子(VEGF)、表皮生长因子(EGF)、成纤维细胞生长因子(bFGF)等。产品溶解于高糖含酚红DMEM中,且非定制产品均添加了50μg/mL

2、 推荐应用

细胞增殖或分化相关的二维或三维培养,以及细胞形态的研究,相关应用主要有:细胞侵袭、血管生成和类器官培养等,模基生物推荐您在细胞迁移和侵袭、血管生成测定时选用标准型基质胶。

3、 产品信息

产品名称

产品货号

规格

存储/运输

保质期

标准型基质胶

082704

10mL

-20°C

24个月

0827045

5mL

082704T

1mL

4、 产品参数

来源:小鼠肿瘤

外观:①颜色:产品表现为黄色-粉红色; ②形态:4℃融解后,呈液态

浓度:蛋白浓度范围在8~12mg/mL之间

内毒素:≤ 10EU/ mL

凝胶时间:室温条件下5-30min凝胶,37°C时成胶速度加快

5、 产品质量控制规范

1、   根据GB 14922.2-2022检测小鼠种群中以下病毒、病原菌寄生虫及细菌结果为阴性。

2、   直接接种法检测产品中是否含真菌、细菌,结果为阴性。

3、   对包括LDEV在内的多种病原体进行广泛的PCR检测,确保对生产过程中使用的原材料进行严格控制。

4、   使用PCR技术扩增产品中支原体序列,结果为阴性。

5、   使用BCA方法测定蛋白浓度。

6、   使用凝胶限度检查法检测产品内毒素水平。

7、   产品与培养基1:2比例稀释后,置于37℃凝胶30分钟,再加入培养基,产品能在37℃环境中保持这种形态5天。

8、   将产品稀释至 70%含量,在细胞培养板中滴加50μL37℃条件下凝胶30分钟,可以形成稳定的凝胶,加入培养基后,在37℃培养箱中能够保持这种形态15天。

9、   每批次产品都能够进行肿瘤细胞侵袭实验和体外血管形成实验。

6、 使用注意事项

a)     温度控制

产品在≤-20℃时是稳定的,分装使用产品以尽可能减少产品的冻融次数。

请不要储存在无霜冰箱中,长期保存时请务必保持产品的冻存状态。

产品解冻时,请将西林瓶包埋在碎冰中,并放置在4℃冰箱中待其融解。

所有接触产品的耗材,请提前降温。

请您在使用过程中不要过长时间地用手握住装有本产品的容具,防止体温使产品凝胶;若在较短时间内造成产品较为厚重粘稠,您可以将本产品重新置于 0 - 4℃ 的环境内1-2 h使其恢复流动性,不影响使用。

b)      避免污染

实验操作人员需严格区分实验操作台、清洁区和污染区,确保插取吸头、加样、丢弃吸头的动作呈单向流动。

c)      其他

产品在每次由冷冻状态变为融解状态时,请适当摇晃或使用移液器吹吸,确保体系内部蛋白分布均匀。

7、 使用方法

模基生物标准型基质胶主要有四种使用方式,我们将为您提供这四种使用方式的的一般操作程序,您可以基于您的实验目的选择合适的使用方式。

方式

方法

适用

主要应用

薄层凝胶

1. 产品解冻后,适当混匀,或根据实验需求使用预冷的培养基稀释,建议浓度不低于1mg/mL

2. 向细胞培养板表面加入50μL/cm²基质胶,平铺均匀,注意避免产生气泡;

3.将培养板放置在 37 ℃,等待30 min形成凝胶即可使用,必要时,吸去上清。

细胞在薄层基质凝胶顶部扩增

细胞迁移和侵袭

原代细胞扩增

薄层包被

1. 产品解冻后,适当混匀,根据实验需求使用预冷的培养基稀释,建议浓度不低于0.1mg/mL

2. 吸取适量体积稀释液移液,覆盖细胞培养板表面,摇匀,建议包被量为0.01-0.02mg/cm²

3.将培养板放置在 37 ℃,孵育至少1h,吸去上清即可使用。

细胞附着在薄层基底膜表面扩增

原代细胞扩增

厚层凝胶

1. 产品解冻后,适当混匀,或根据实验需求使用预冷的培养基稀释,建议基质胶占比 > 67%

2. 向细胞培养板表面加入150-200μL/cm²基质胶,平铺均匀,注意避免产生气泡;

3.将培养板放置在 37 ℃,等待30 min形成凝胶即可使用。

细胞在厚层基质凝胶上

形成三维结构

体外血管生成

主动脉环

凝胶包埋

1. 产品提前解冻备用;

2. 准备所需的细胞,用基质胶重悬,建议基质胶占比>70%

3. 向细胞培养板表面加入15-20μL/cm²,注意避免产生气泡;

4.将培养板放置在 37 ℃,30 min形成包裹细胞的凝胶,向培养板内添加合适的培养基。

细胞在基质胶内扩增、发育

类器官培养

肿瘤球状体侵袭

V2.0

更新时间:2025/6/12

8、 文献应用

    1、 m6A Modification of Long Non-Coding RNA HNF1A-AS1 Facilitates Cell Cycle Progression in Colorectal Cancer viaIGF2BP2-Mediated CCND1 mRNA StabilizationIF=5.1 血管形成)

    2、 SIRT6PreventsGlucocorticoid-InducedOsteonecrosisofthe FemoralHeadinRatsIF=7.3 血管形成)

    3、 Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effectsIF=6.51  血管形成)

    4、 3D-printed Sr2ZnSi2O7 scaffold facilitates vascularized bone regeneration through macrophage immunomodulationIF=6.006  血管形成)

    5、 Long noncoding RNA H19 synergizes with STAT1 to regulate SNX10 in rheumatoid arthritisIF=4.17 侵袭实验、血管生成)

    6、 Heteronuclear Ru(II)-Re(I) complexes as potential photodynamic anticancer agents with anti-metastatic and anti-angiogenic activitiesIF=4.336 血管生成)

    7、 Efficient delivery of VEGF-A mRNA for promoting diabetic wound healing via ionizable lipid nanoparticlesIF=6.51 血管形成)

    8、 Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMTIF=6.65 血管生成 )

    9、 Recombinant Human Arresten and Canstatin Inhibit Angiogenic Behaviors of HUVECs via Inhibiting the PI3K/Akt Signaling PathwayIF=6.2 血管生成)

    10、 H2S-releasing versatile hydrogel dressing with potent antimicrobial, anti-inflammatory, epithelialization and angiogenic capabilities for diabetic wound healingIF=15.1 血管生成)

    11、 METTL3-mediated m6A RNA modification promotes corneal neovascularization by upregulating the canonical Wnt pathway during HSV-1 infectionIF=4.8 血管生成)

    12、 Down-regulation of histone deacetylase 7 reduces biological activities of retinal microvascular endothelial cells under high glucose condition and related mechanismIF=1.4 血管生成)

    13、 Phenylboronic Ester-Bridged Chitosan/Myricetin Nanomicelle for Penetrating the Endothelial Barrier and Regulating Macrophage Polarization and Inflammation IF=5.8   血管形成)

    14、 Efficient delivery of VEGFA mRNA for promoting wound healing via ionizable lipid nanoparticlesIF=3.5 血管形成)

    15、 Activation of angiotensin II type 2 receptor attenuates lung injury of collagen-induced arthritis by alleviating endothelial cell injury and promoting Ly6Clo monocyte …(IF=5   血管形成)

    16、  SIRT6 Prevents Glucocorticoid-Induced Osteonecrosis of the Femoral Head in RatsIF=7.3    血管形成)

    17、 Regulation of the Osteogenic Microenvironment by Pioglitazone-Loaded Polylactic Glycolic Acid Nanosphere Composite Scaffolds to Promote Vascularization and Bone RegenerationIF=6.7  血管形成)

    18、 A DoseDependent Spatiotemporal Response of Angiogenesis Elicited by Zn Biodegradation During The Initial Stage of Bone RegenerationIF=10       血管形成)

    19、 MCC950 alleviates seizure severity and angiogenesis by inhibiting NLRP3/IL-1β signaling pathway-mediated pyroptosis in mouse model of epilepsyIF=5.6 血管形成)

    20、 An injectable carrier for spatiotemporal and sequential release of therapeutic substances to treat myocardial infarctionIF=10.8 血管形成)

    21、 Sodium selenite ameliorates silver nanoparticles induced vascular endothelial cytotoxic injury by antioxidative properties and suppressing inflammation through activating the Nrf2 signaling pathwayIF=3.9 血管形成)

    22、 Hypoxic microenvironment reconstruction with synergistic biofunctional ions promotes diabetic wound healingIF=10 血管形成)

    23、 Temperature-sensitive hydrogel dressing loaded with nicotinamide mononucleotide accelerating wound healing in diabetic miceIF=7.5 血管形成)

    24、 Injectable photocuring silk fibroin-based hydrogel constructs antioxidant micro-environment for skin repairIF=7 血管形成)

    25、 Temperature-sensitive hydrogel dressing loaded with nicotinamide mononucleotide accelerating wound healing in diabetic miceIF=6.9  血管形成)

    26、 Discovery of novel amide derivatives against VEGFR-2/tubulin with potent antitumor and antiangiogenic activityIF=4.5 血管形成)

    27、 Melatonin Attenuates Diabetic Retinopathy byRegulating EndMT of Retinal Vascular EndothelialCells via Inhibiting the HDAC7/FOXO1/ZEB1 AxisIF=8.3  血管形成)

    28、 Biomimetic nanocomplex based cornealneovascularization theranostics Melatonin Attenuates Diabetic Retinopathy by Regulating EndMT of Retinal Vascular Endothelial Cells via Inhibiting the HDAC7/FOXO1/ZEB1 AxisIF=10.5 血管形成)

    29、 Microenvironment Remodeling Self-Healing Hydrogel for Promoting Flap SurvivalIF=8.1 血管形成实验)

    30、 Multifunctional Exosomes Derived from M2 Macrophages with Enhanced Odontogenesis, Neurogenesis and Angiogenesis for Regenerative Endodontic Therapy: An In Vitro and In Vivo InvestigationIF=3.9 血管生成)

    31、 Multifunctional surface of the nano-morphic PEEK implant with enhanced angiogenic, osteogenic and antibacterial propertiesIF=5.6 血管生成)

    32、 ABCA12 Promotes Proliferation and Migration and Inhibits Apoptosis of Pancreatic Cancer Cells Through the AKT Signaling Pathway ABCA12   IF=4.77 侵袭实验.

    33、 Progranulin promotes proliferation, migration, and invasion of eutopicendometrial stromal cells in patients with endometriosis via the PI3K/Akt signaling pathway Progranulin  IF=4.5    侵袭实验.

    34、 Exploration of fetal growth restriction induced by vitamin D deficiency in rats via Hippo-YAP signaling pathwayIF=3.28 侵袭实验.

    35、 DEPDC1 as a crucial factor in the progression of human osteosarcoma DEPDC1  IF=4.7  侵袭实验)

    36、 TIAM2 Contributes to Osimertinib Resistance, Cell Motility,and Tumor-Associated Macrophage M2-like Polarization in Lung AdenocarcinomaIF=6.2 侵袭实验)

    37、 SUMOylation of TUFT1 is essential for gastric cancer progression through AKT/mTOR signaling pathway activation IF=6.5 侵袭实验)

    38、 Glycoside Combinations of BYHWD Inhibit Atherosclerotic Angiogenesis Via STAT3/HIF-1/VEGF Pathway BYHWDIF=3.6 侵袭实验)

    39、 "The Core-Targeted RRM2 Gene of Berberine HydrochloridePromotes Breast Cancer Cell Migration and Invasion via theEpithelial–Mesenchymal TransitionIF=5.21    侵袭实验)

    40、  HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanomaIF=5.8 侵袭实验)

    41、 Elucidating the pharmacological effects of Compound Kushen injection on MYC-P15-CCND1 signaling pathway in nasopharyngeal carcinoma-An in vitro studyIF=5.4     侵袭实验)

    42、 The Core-Targeted RRM2 Gene of Berberine Hydrochloride Promotes Breast Cancer Cell Migration and Invasion via the EpithelialMesenchymal TransitionIF=4.6 侵袭实验)

    43、 Enhance Mitochondrial Damage by Nuclear Export Inhibition to Suppress Tumor Growth and Metastasis with Increased Antitumor Properties of MacrophagesIF=9.5       侵袭实验)

    44、 M2 Macrophage-Derived Exosomal lncRNA MIR4435-2HG Promotes Progression of Infantile Hemangiomas by Targeting HNRNPA1IF=8       侵袭实验)

    45、 Nuciferine Inhibits Oral Squamous Cell Carcinoma Partially through Suppressing the STAT3 Signaling PathwayIF=5.6 侵袭实验)

    46、 Prognostic and immunological role of cancer-associated fibroblasts-derived exosomal protein in esophageal squamous cell carcinomaIF=5.6     侵袭实验)

    47、 TNFR2 promotes pancreatic cancer proliferation, migration, and invasion via the NF-κB signaling pathwayIF=5.2 侵袭实验)

    48、 VAMP8 suppresses the metastasis via DDX5/β-catenin signal pathway in osteosarcomaIF=3.6    侵袭实验)

    49、 A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinomaIF=7.3     侵袭实验)

    50、 6-Phosphogluconate dehydrogenase promotes glycolysis and fatty acid synthesis by inhibiting the AMPK pathway in lung adenocarcinoma cellsIF=9.1 transwell assay

    51、 TREM1+ tumor-associated macrophages secrete CCL7 to promote hepatocellular carcinoma metastasisIF=2.7   Wound-healing assay and transwell assay




在线咨询

留言框

  • 产品:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 省份:

  • 详细地址:

  • 补充说明:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7